|
Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - NanoString Technologies |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - NanoString Technologies |
|
|
Employment - NanoString Technologies |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen (I); Celgene (I); NanoString Technologies (I); Novartis (I); Pfizer (I); Roche Pharma AG (I) |
Consulting or Advisory Role - AstraZeneca (I); Celgene (I); Genomic Health (I); Novartis (I); Roche Pharma AG (I); Sandoz (I); Wilex (I) |
Research Funding - Boehringer Ingelheim (I); Novartis (I); Pfizer (I); Roche/Genentech (I) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; NanoString Technologies; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Celgene; Genomic Health; Novartis; Roche/Genentech; Sandoz; Wilex |
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |